1. Sheean ME, Malikova E, Duarte D, Capovilla G, Fregonese L, Hofer M, Magrelli A, Mariz S, Mendez-Hermida F, Nistico R, Leest T, Sipsas NV, Tsigkos S, Vitezic D, Larsson K, Sepodes B, Stoyanova-Beninska V. Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases. Drug Discov Today. 2019 Nov 5.
  2. Holtkamp F, Gudmundsdottir H, Maciulaitis R, Benda N, Thomson A, Vetter T. Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators. Am J Kidney Dis. 2019 Oct 25.
  3. Ghalandari N, Dolhain RJEM, Hazes JMW, Siezen CLE, van der Laan JW, Crijns HJ, van Puijenbroek EP, van der Woude CJ. The pre- and post-authorisation data published by the European Medicines Agency on the use of Biologics during pregnancy and lactation. Br J Clin Pharmacol. 2019 Oct 21.
  4. Potts J, Genov G, Segec A, Raine J, Straus S, Arlett P. Improving the Safety of Medicines in the EU: From signals to action. Clin Pharmacol Ther. 2019 Oct 17.
  5. Hoeve CE, Francisca RDC, Zomerdijk I, Sturkenboom MCJM, Straus SMJM. Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union. Drug Saf. 2019 Oct 16.
  6. Weersink RA, Timmermans L, Monster-Simons MH, Mol PGM, Metselaar HJ, Borgsteede SD, Taxis K. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment. Front Pharmacol. 2019 Sep 17;10:1031.
  7. van Hunsel F, Gardarsdottir H, de Boer A, Kant A. Measuring the impact of pharmacovigilance activities, challenging but important. Br J Clin Pharmacol. 2019 Oct;85(10):2235-2237.
  8. Gispen-de Wied CC, Weemers J, Boon W, Mol PGM, Stolk P. Future of the drug label: Perspectives from a multistakeholder dialogue.Br J Clin Pharmacol. 2019 Oct;85(10):2442-2445.
  9. McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, Kurz X, Mol PGM. Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 2019 Nov;42(11):1343-1351. Erratum in: Drug Saf. 2019 Sep 5.
  10. Veening-Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen-de Wied CC, Moors EHM, Schellekens H. Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. Eur J Pharmacol. 2019 Sep 15;859:172524.
  11. Bernabe RC, van Thiel GJMW, Breekveldt NS, Gispen CC, van Delden JJM. Regulatory sanctions for ethically relevant GCP violations. Drug Discov Today. 2019 Jul 6. pii: S1359-6446(19)30081-9.
  12. Haberkamp M, Moseley J, Athanasiou D, de Andres-Trelles F, Elferink A, Rosa MM, Magrelli A. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul Disord. 2019 Jul;29(7):514-516.
  13. Albrecht W, Kappenberg F, Brecklinghaus T, Stoeber R, Marchan R, Zhang M, Ebbert K, Kirschner H, Grinberg M, Leist M, Moritz W, Cadenas C, Ghallab A, Reinders J, Vartak N, van Thriel C, Golka K, Tolosa L, Castell JV, Damm G, Seehofer D, Lampen A, Braeuning A, Buhrke T, Behr AC, Oberemm A, Gu X, Kittana N, van de Water B, Kreiling R, Fayyaz S, van Aerts L, Smedsrød B, Ellinger-Ziegelbauer H, Steger-Hartmann T, Gundert-Remy U, Zeigerer A, Ullrich A, Runge D, Lee SML, Schiergens TS, Kuepfer L, Aguayo-Orozco A, Sachinidis A, Edlund K, Gardner I, Rahnenführer J, Hengstler JG. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol. 2019 Jun;93(6):1609-1637.
  14. Braakhuis HM, Theunissen PT, Slob W, Rorije E, Piersma AH. Testing developmental toxicity in a second species: are the differences due to species or replication error? Regul Toxicol Pharmacol. 2019 Oct;107:104410.
  15. Denig P, van Puijenbroek EP, Soliman N, Mol PGM, de Vries ST. Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1175-1179.
  16. Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, Gispen-de Wied CC, Schellekens H, van Meer PJK. A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLoS One. 2019 Jun 13;14(6):e0218014. Erratum in: PLoS One. 2019 Jul 22;14(7):e0220325.
  17. Dekker MJHJ, Bouvy JC, O'Rourke D, Thompson R, Makady A, Jonsson P, Gispen-de Wied CC. Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease. Front Med (Lausanne). 2019 May 7;6:73.
  18. Mieiro L, Beuscart JB, Knol W, Van Riet-Nales D, Orlu M. Achieving appropriate medication for older adults: A multidimensional perspective. Maturitas. 2019 Jun;124:43-47.
  19. Ollivier C, Sun H, Amchin W, Beghetti M, Berger RMF, Breitenstein S, Garnett C, Gullberg N, Hassel P, Ivy D, Kawut SM, Klein A, Lesage C, Migdal M, Nije B, Odermarsky M, Strait J, de Graeff PA, Stockbridge N. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. J Am Heart Assoc. 2019 May 21;8(10):e011306.
  20. van der Laan JW, Benson CT, Janssens W, Bos J, Stahl E, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD. Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018. Ther Innov Regul Sci. 2019 May 13:2168479019843514.
  21. Lenić I, Blake K, Garcia-Arieta A, Potthast H, Welink J. Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications. Clin Transl Sci. 2019 Sep;12(5):490-496.
  22. Krause S, Lacana E, Welch J, Shapiro M, Downey C, Chung J, Zhou Q, Van Der Plas M, Depatie C, Ingram B, Srebalus-Barnes C, Polozova A, Rellahan B, Choi D, Burdick R, Stangler T, Shacter E. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications. PDA J Pharm Sci Technol. 2019 Jul-Aug;73(4):401-416.
  23. Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentová K, Vertzoni M, Čepo DV, Corsetti M. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. Eur J Pharm Sci. 2019 Jun 15;134:31-59.

Go to all publications of the MEB.